Relatively-subdued COVID-19 fears
23/03/20 -"With aggravating COVID-19 fears and a material effect on the pharma supply chain – especially with respect to APIs, other than already known biosimilar risks, near-term earnings pressure is ..."
Pages
69
Language
English
Published on
23/03/20
You may also be interested by these reports :
22/10/26
The Q3 sales were ahead of the street’s expectations, driven by healthy growth across both segments. The beat, though, received support from a ...
22/10/26
Ipsen reported a robust Q3, resulting in an upgraded 2026 guidance. While we may revise our estimates upwards, we do not anticipate a significant ...
22/10/26
A guidance upgrade on top of the modest outlook uplift in July 2026 reflects UCB’s habit of making modest promises and then over-delivering. ...
20/10/26
The Q3 sales growth surpassed the full-year guidance range, backed by healthy growth in companion and farm animal segments across geographies. The ...